Shanghai, China · Founded 2018 · In IPO Registration
Operator of a biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions. Alebund Pharmaceuticals is based in Shanghai, China and was founded in 2018. Its last reported valuation was $530 million in Oct 2025. It has raised $270 million.
Last reported valuation
$530.5M
Oct 2026
Priced at
—
Total raised
$269.8M
Last round
—
No prints on record
No secondary trades in Alebund Pharmaceuticals shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Alebund Pharmaceuticals with a free account
·The complete investor list: 25 names
·Watch Alebund Pharmaceuticals: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Alebund Pharmaceuticals stock.
